Urol. praxi. 2016;17(3):143-144

LUTS u爉u均: komu nab韉nout antimuskarinikum v爇ombinaci s燼lfablok醫orem?

Zve鴈jn靚o: 1. srpen 2016  Zobrazit citaci

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
LUTS u爉u均: komu nab韉nout antimuskarinikum v爇ombinaci s燼lfablok醫orem? Urol. praxi. 2016;17(3):143-144.
St醜nout citaci

Reference

  1. Rees J, Bultitude M, Challacombe B. The management of lower urinary tract symptoms in men. BMJ. 2014; 348: g3861. P鴈j韙 k p鵹odn韒u zdroji... P鴈j韙 na PubMed...
  2. Hanu� T, Z醡e鑞韐 L, Dole綼l T, Karmaz韓ov� Z. Occurrence of overactive bladder in patients with benign prostatic hyperplasia in the Czech Republic. Urol Int. 2011; 86(4): 407-413. P鴈j韙 k p鵹odn韒u zdroji... P鴈j韙 na PubMed...
  3. Peters TJ, Donovan JL, Kay HE, et al. The International Continence Society "Benign Prostatic Hyperplasia" Study: the botherosomeness of urinary symptoms. J Urol. 1997; 157(3): 885-889. P鴈j韙 k p鵹odn韒u zdroji... P鴈j韙 na PubMed...
  4. H鋕kinen JT, Hakama M, Huhtala H, et al. Impact of LUTS using bother index in DAN-PSS-1 questionnaire. Eur Urol. 2007; 51(2): 473-477; discussion 477-478. P鴈j韙 k p鵹odn韒u zdroji... P鴈j韙 na PubMed...
  5. van Kerrebroeck P, Chapple C, Drogendijk T, et al. Combination therapy with solifenacin and tamsulosin oral controlled absorption system in a single tablet for lower urinary tract symptoms in men: efficacy and safety results from the randomised controlled NEPTUNE trial. Eur Urol. 2013; 64(6): 1003-1012. P鴈j韙 k p鵹odn韒u zdroji... P鴈j韙 na PubMed...
  6. Drake MJ, Chapple C, Sokol R, et al. Long-term safety and efficacy of single-tablet combinations of solifenacin and tamsulosin oral controlled absorption system in men with storage and voiding lower urinary tract symptoms: results from the NEPTUNE Study and NEPTUNE II open-label extension. Eur Urol. 2015; 67(2): 262-270. P鴈j韙 k p鵹odn韒u zdroji... P鴈j韙 na PubMed...
  7. Chapple CR, Khullar V, Gabriel Z, et al.The effects of antimuscarinic treatments in overactive bladder: an update of a systematic review and meta-analysis. Eur Urol. 2008; 54(3): 543-562. P鴈j韙 k p鵹odn韒u zdroji... P鴈j韙 na PubMed...
  8. Gravas S, et al. EAU guidelines on the treatment of non-neurogenic male LUTS. 2016. http://uroweb.org/
  9. Abrams P, Avery K, Gardener N, et al. The International Consultation on Incontinence Modular Questionnaire: www.iciq.net. J Urol. 2006; 175(3 Pt 1): 1063-1066; discussion 1066. P鴈j韙 k p鵹odn韒u zdroji... P鴈j韙 na PubMed...
  10. Kaplan SA, McCammon K, Fincher R, et al. Safety and tolerability of solifenacin add-on therapy to alphablocker treated men with residual urgency and frequency. J Urol 2009; 182(6): 2825-30. P鴈j韙 k p鵹odn韒u zdroji... P鴈j韙 na PubMed...




Urologie pro praxi

V峋en� pan�, pane,
upozor騯jeme V醩, 緀 webov� str醤ky, na kter� hodl醫e vstoupit, nejsou ur鑕ny 筰rok� ve鴈jnosti, nebo� obsahuj� odborn� informace o l殍iv齝h ppravc韈h, v鑕tn� reklamn韈h sd靗en�, vztahuj韈� se k l殍iv齧 ppravk鵰. Tyto informace a sd靗en� jsou ur鑕na v齢radn� odborn韐鵰 dle �2a z醟ona �.40/1995 Sb., tedy osob醡 opr醰n靚齧 l殍iv� ppravky p鴈depisovat nebo vyd醰at (d醠e jen odborn韐).
Vezm靦e v potaz, 緀 nejste-li odborn韐, vystavujete se riziku ohro緀n� sv閔o zdrav�, poppad� i zdrav� dal鬼ch osob, pokud byste z韘kan� informace nespr醰n� pochopil(a) 鑙 interpretoval(a), a to zejm閚a reklamn� sd靗en�, kter� mohou b齮 sou栳st� t靋hto str醤ek, 鑙 je vyu緄l(a) pro stanoven� vlastn� diagn髗y nebo l殍ebn閔o postupu, a� u� ve vztahu k sob� osobn� nebo ve vztahu k dal鬼m osob醡.

Prohla箄ji:

  1. 緀 jsem se s ve uveden齧 pou鑕n韒 sezn醡il(a),
  2. 緀 jsem odborn韐em ve smyslu z醟ona �.40/1995 Sb. o regulaci reklamy v platn閙 zn靚� a jsem si v靌om(a) rizik, kter齧 by se jin� osoba ne� odborn韐 vstupem na tyto str醤ky vystavovala.


Ne

Ano

Pokud va筫 prohl峁en� nen� pravdiv�, upozor騯jeme V醩,
緀 se vystavujete riziku ohro緀n� sv閔o zdrav�, poppad� i zdrav� dal鬼ch osob.